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Abstract
Background
The polygenic risk score (PRS) developed for coronary artery disease (CAD) is known to be
effective for classifying patients with CAD and predicting subsequent events. However, the
PRS was developed mainly based on the analysis of Caucasian genomes and has not been
validated for East Asians. We aimed to evaluate the PRS in the genomes of Korean early-
onset AMI patients (n = 265, age�50 years) following PCI and controls (n = 636) to examine
whether the PRS improves risk prediction beyond conventional risk factors.
Results
The odds ratio of the PRS was 1.83 (95% confidence interval [CI]: 1.69–1.99) for early-
onset AMI patients compared with the controls. For the classification of patients, the area
under the curve (AUC) for the combined model with the six conventional risk factors (diabe-
tes mellitus, family history of CAD, hypertension, body mass index, hypercholesterolemia,
and current smoking) and PRS was 0.92 (95% CI: 0.90–0.94) while that for the six conven-
tional risk factors was 0.91 (95% CI: 0.85–0.93). Although the AUC for PRS alone was 0.65
(95% CI: 0.61–0.69), adding the PRS to the six conventional risk factors significantly
improved the accuracy of the prediction model (P = 0.015). Patients with the upper 50% of
PRS showed a higher frequency of repeat revascularization (hazard ratio = 2.19, 95% CI:
1.47–3.26) than the others.
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Conclusions
The PRS using 265 early-onset AMI genomes showed improvement in the identification of
patients in the Korean population and showed potential for genomic screening in early life to
complement conventional risk prediction.
Introduction
The polygenic risk score (PRS) is a quantitative genetic risk score, determined by the cumula-
tive impact of genome-wide variants, used to improve risk prediction for common chronic
diseases [1]. A study of the PRS for coronary artery disease (CAD) reported a significant
improvement in classification when the PRS was combined with conventional risk factors [2].
The study also reported the more efficient classification of patients using the PRS in a younger
age group (age <55 years) than in an older age group (age�55 years). The PRS also showed
predictive power for all-cause mortality after cardiac catheterization [3].
In 2019, a study on early-onset myocardial infarction (mean age of the patients = 48 years)
revealed 10-fold higher classification capacity of the PRS compared to a classification based on
monogenic mutations [4]. However, the study did not fully evaluate the contribution of the
PRS when it was combined with conventional risk factors, such as smoking, for the classifica-
tion of patients. Additionally, the proportion of high PRS carriers was insignificant in the
Asian patient group. This is probably because of the small number of Asian patients (n = 40,
1.9% among patients) or the use of the PRS derived from studies performed mainly on Cauca-
sian individuals [5].
The incidence of acute myocardial infarction (AMI) varies by ethnic group, with particu-
larly lower values in East Asian populations than Western populations [6,7]. This variation
among ethnic groups may be caused by differences in genetic factors since East Asian and
Caucasian populations are genetically distinct [8]. Therefore, validating the applicability of the
PRS in a different ethnic group is critical, particularly for East Asian patients.
Herein, we applied the whole-genome sequencing-based PRS in 265 Korean early-onset
AMI patients following percutaneous coronary intervention (PCI). We evaluated the validity
of the PRS in Korean patients with early-onset AMI in terms of the classification of patients
and the prediction of cardiovascular events after PCI.
Materials and methods
Study population
We obtained the Korean variome and clinical information data from KGP. The KGP is a joint
project facilitated by the Personal Genome Project (PGP) at Harvard Medical School, National
Center for Standard Reference Data of Korea, Clinomics, Inc., and KOGIC (Korean Genomics
Center) of UNIST. It aims to generate a combination of whole-genome sequencing data, ques-
tionnaires, and clinical measurements of participants in Korea. The Korean patients were hos-
pitalized with a diagnosis of and treatment for an ST-segment elevation myocardial infarction
or non-ST-segment elevation myocardial infarction; they were�50 years old and had under-
gone PCI at three hospitals. The Korean control subjects were selected from among the KGP
individuals without a history of AMI, angina, or heart attack. Subjects who were taking drugs
for CAD were excluded. Written informed consent was obtained from all study participants
by the clinicians in the participating hospitals. The present study was approved by the UNIST
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identifying or sensitive patient information.
Therefore, raw sequencing data, individual
genotype information, and clinical trait data will be
available upon request and after an approval from
the Korean Genomics Center’s review board in
UNIST. Information about the KGP, present dataset
(Cardiomics) and other related data sharing can be
found at http://koreangenome.org/Cardiomics.
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Genomic variant identification
The Korean variome was derived from KGP. A detailed description of the sequencing and
genotyping is described in the previous KGP initiation paper [8]. Briefly, the adapters were
trimmed using Cutadapt (ver 1.9.1) [9]. The mapped BAM files were sorted using genomic
coordination in Picard (ver. 2.14.0) with the SortSam module. Duplicated reads were
marked using Picard (ver. 2.14.0) with the MarkDuplicates module. Mapping quality was
calibrated using the BaseRecalibrator module in the Genome Analysis Tool Kit (ver. 3.7)
[10]. Joint variant genotyping was performed using HaplotypeCaller in the Genome Analy-
sis Tool Kit with the ‘-stand_call_conf 30’ option. To extract variants in the callable genomic
region, variants were filtered based on strict accessible regions as defined by the 1,000
Genome Project [11].
PRS calculation
We calculated the PRSs of the patients and controls based on the reported list of allele variants
and their risk weights for CAD [1]. Briefly, this risk prediction model was originally derived by
running the LDpred algorithm on the estimated genetic effects from a meta-analysis of CAD
[5,12]. The acquired variome from KGP was lifted-over to hg19 by CrossMap (ver 0.2.7), and
the PRS was calculated using PLINK (ver 1.90) with the “—score” option [13,14]. Downstream
analyses were performed using R version 3.6.3 software [15]. The calculated PRS was normal-
ized by inverse normal transformation.
Patient follow-up and outcome measurements
We conducted the follow-up of patients at outpatient clinic visits and through telephonic con-
tact. An independent clinical event committee whose members were blinded to the clinical,
angiographic, and genetic data adjudicated all events. The vital status of all patients was cross-
checked using Korean Health System’s unique identification numbers. In this way, mortality
was confirmed, even in patients who were lost during follow-up. The adverse events included
all causes of death, MI, and repeat revascularization. All clinical outcomes were defined
according to the Academic Research Consortium [16].
Statistical analysis
Downstream analyses were performed using R version 3.6.3 software [15]. The calculated
PRSs were standardized to zero-mean and one-standard deviation by inverse normal transfor-
mation. The distribution of the PRSs was compared between patients and controls using the
Wilcoxon ranksum test. The correlation between the PRS and age was assessed using Spear-
man’s rank correlation. A high PRS in the distribution comparison analysis was defined as a
PRS higher than the top 5% of the control distribution [1,4]. Receiver operating characteristic
curve analysis was conducted using the R package pROC (ver 1.16.1) [17]. The paired test was
conducted for the comparison of the areas under the curve (AUCs) among predictors. The
PRS was standardized among patients, and the patients were divided into an upper-50% PRS
group and a lower-50% PRS group for survival analysis. Survival analysis was conducted using
R package survival (ver 3.1–11) [18].
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Results
Sample characteristics
A total of 901 whole-genomes from 265 patients with early-onset AMI (�50 years old, number
of male patients: 252, number of female patients: 13), and 636 controls (see Methods; Table 1)
were sequenced and analysed. The mean age of the patients and controls was 44.6 years
(median = 46, interquartile range [IQR]: 42 to 46) and 43.8 years (median = 43, IQR: 29 to 57),
respectively. The median follow-up period in the patient group was 43 months (IQR: 16 days
to 14.8 years). The proportions of current smokers in the patient and control groups were
72.7% and 12.9%, respectively. A total of 75.1% of the male patients and 22.6% of the male con-
trols were current smokers.
Differences in the PRS between the patients and controls
The distribution of PRSs was significantly higher in patients than in controls (average PRSs
were 0.40 and -0.17 for patients and controls, respectively; P<0.001). The odds ratio of the
PRS for early-onset AMI patients compared with the controls was 1.83 (95% confidence inter-
val [CI]: 1.69–1.99, P<0.001). The proportion of individuals who show a high PRS which was
defined as a PRS higher than the top 5% in the control distribution was significantly larger
among the patients (58 of 265, 21.9%) than among the controls (32 of 636, 5.0%, P<0.001). In
the patients group, the PRS and age (age-at-event) showed a significantly negative correlation
(Spearman’s rho = -0.14, P = 0.025), while not significant correlation in the control group
(Spearman’s rho = 0.03, P = 0.463).
Classification power of PRS for patient classification
The AUC for the PRS was 0.65 (95% CI: 0.61–0.69). The AUC for the classification model
including all six conventional risk factors was 0.91 (95% CI: 0.89–0.93) and that of the classifi-
cation model including the six conventional risk factors and the PRS was 0.92 (95% CI: 0.90–
0.94). The contribution of the PRS to the six conventional risk factors was significant
(P = 0.015) (Fig 1). Among conventional risk factors, current smoking showed the highest
Table 1. Baseline characteristics of patients with early-onset AMI and controls.
Variables Early-onset AMI (n = 265) Control (n = 636)
Male 252 (95.1) 323 (50.8)
Age, years 46 (42–46) 43 (29–57)
Body mass index 25.5 ± 3.8 24.0 ± 3.5
Hypertension 78 (30.8) 93 (14.6)
Diabetes mellitus 38 (15.0) 35 (5.5)
Current smoking 178 (72.7) 82 (12.9)
Hypercholesterolemia 230 (86.8) 294 (46.2)
Family history of CAD 41 (16.4) 21 (3.3)
Lipid levels, mg/dL
Total cholesterol, mg/dl 205.8 ± 47.6 179.9 ± 34.2
LDL cholesterol, mg/dl 127.5 ± 43.1 116.0 ± 33.0
HDL cholesterol, mg/dl 42.7 ± 12.9 57.4 ± 13.9
Triglycerides, mg/dl 199.5 ± 147.2 116.0 ± 77.1
AMI, acute myocardial infarction; family history of CAD, 1st degree family history of coronary artery disease; LDL, low-density lipoprotein; HDL, high-density
lipoprotein. Values are mean ± SD, median (interquartile range, 25th—75th), or n (%).
https://doi.org/10.1371/journal.pone.0246538.t001
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AUC of 0.80 (95% CI: 0.77–0.83) compared to other factors such as hypercholesterolemia
(AUC = 0.70, 95% CI: 0.68–0.73), body mass index (0.64, 95% CI: 0.60–0.68), hypertension
(0.58, 95% CI: 0.55–0.61), family history of CAD (0.57, 95% CI: 0.54–0.59), and diabetes melli-
tus (0.55, 95% CI: 0.52–0.57).
The AUC for the PRS was significantly higher in the younger age group (AUC = 0.69, 95%
CI: 0.63–0.75) than in the older age group (AUC = 0.58, 95% CI: 0.50–0.66) (P = 0.029) when
we compared the classification accuracy of the PRS between younger subjects (25< age� 45
years, 130 patients and 248 controls) and older subjects (45< age� 50 years, 134 patients and
72 controls) (Fig 2). Combining the PRS with the conventional risk factors increased the classi-
fication accuracy in both the younger (AUC of conventional factors = 0.92, 95% CI: 0.90–0.95;
Fig 1. Receiver operator characteristic curve and AUC for conventional risk factors and combined models. AUC, area under the
curve; CAD: coronary artery disease; CI: confidence interval; PRS, polygenic risk score.
https://doi.org/10.1371/journal.pone.0246538.g001
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AUC of conventional factors and PRS = 0.94, 95% CI: 0.91–0.96; P = 0.038) and the older
groups (AUC of the conventional factors: 0.90, 95% CI: 0.86–0.95; AUC of the conventional
factors and PRS: 0.91, 95% CI: 0.86–0.95; P = 0.423). However, the additional improvment in
discrimination accuracy was significant only in the younger group.
Prediction power of the PRS for subsequent cardiovascular events
A significant cumulative event was only identified for repeat revascularization when we
assessed the classification power of the PRS for predicting a subsequent cardiovascular event
after PCI. The cumulative event of all causes of death or AMI was not significant (all causes of
death P = 0.944, AMI P = 0.957), possibly because of the small sample size and the small num-
ber of events (all causes of death: n = 5, AMI: n = 4). Patients with upper 50% PRS among
patients showed a significantly higher frequency of repeat revascularization (hazard
ratio = 2.19, 95% CI: 1.47–3.26, P = 0.049; Fig 3). PRS was the only variable that was
Fig 2. Receiver operating characteristic curve and AUC for PRS stratified by age. AUC, area under the curve; CI:
confidence interval; PRS, polygenic risk score.
https://doi.org/10.1371/journal.pone.0246538.g002
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significantly and independently associated with the cumulative event of repeat revasculariza-
tion after PCI in both univariable and multivariable analyses conducted with the inclusion of
all the conventional risk factors (Table 2).
Discussion and conclusions
The PRS distribution was significantly higher in patients than in the controls when we evalu-
ated the discrimination and prediction power of the PRS for CAD in Korean early-onset AMI
patients following PCI. The odds ratio of the PRS was significantly higher (1.83) in the patient
group. The proportion of high PRS carriers was also significantly higher in patients than in
Fig 3. Comparison of the cumulative incidence of repeat revascularization events between the upper-50% and lower-50% PRS groups. Number at
risk, the number of followed individuals; number of events, the number of individuals with repeat revascularization; PRS, polygenic risk score.
https://doi.org/10.1371/journal.pone.0246538.g003
Table 2. Predictive power of conventional risk factors and PRS for repeat revascularization after PCI.
Predictors Univariable analysis Multivariable analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Body mass index 0.96 0.88–1.04 0.314 0.92 0.83–1.03 0.135
Hypertension 0.74 0.32–1.75 0.495 0.88 0.36–2.18 0.787
Current smoking 0.67 0.31–1.45 0.313 0.58 0.26–1.31 0.191
Diabetes mellitus 1.44 0.59–3.55 0.424 1.41 0.54–3.69 0.478
Hypercholesterolemia 3.33 0.45–24.50 0.238 3.56 0.43–29.40 0.238
Family history of CAD 0.77 0.27–2.20 0.621 0.63 0.21–1.91 0.411
Polygenic risk score 1.64 1.12–2.38 0.010 1.65 1.11–2.46 0.014
CI, confidence interval; Family history of CAD, 1st degree family history of coronary artery disease; Predictors in the multivariable analysis included all conventional
risk factors in the univariable analysis.
https://doi.org/10.1371/journal.pone.0246538.t002
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controls. This seemed to indicate a significant increase in discrimination accuracy when it was
combined with conventional risk factors. We also observed a significantly higher frequency of
repeat revascularization events in the patient group with PRSs that fell within the upper 50%
than in the patient group with those that fell within the lower 50%. This suggests that the PRS
can be a useful indicator as genetic screening which make AMI patients notice the possiblity of
repeat occurrences of revascularization after PCI. Our investigation indicates that the PRS is
also applicable to Korean early-onset AMI patients.
The AUC for current smoking status was the highest predictor in the conventional predic-
tors. One possible issue is that our patient cohort contained a higher proportion of current
smokers (patients: 72.7%, controls: 12.9%) than a previous study on early-onset AMI (patients:
51%, controls: 12%) [4]. This difference in the proportions of smokers between the previous
study and the present study could be due to the difference in the proportion of males among
patients between the previous (34%) and present studies (95.1%). Furthermore, the proportion
of current smokers among both male patients (75.1%) and male controls (22.6%) in the pres-
ent study was not similar to the reported proportion of smokers among Korean males (40 to
50%) [19]. The low proportion of current smokers among the controls could have introduced
a strong bias in our analyses. Another sampling bias is the way in which the control individuals
were recruited. The controls were healthy volunteers from the Korean Genome Project (KGP)
who are probably interested in maintaining good healthOverall, the high AUC for current
smoking status in the present study could have been biased. The classification accuracy based
on the current smoking status may be lower in practice. On the other hand, the sample recruit-
ment bias could have caused the underestimation of PRS accuracy.
Nevertheless, PRS measurement, if cost and time for sequencing are considered, can be per-
formed when conventional risk factors cannot be determined. In this context, identifying
genetic risk at birth or in early life would be the earliest and the most cost-effective option. The
negative correlation between age-at-event and the PRS of the patient group and the higher dis-
crimination accuracy of the PRS in the younger group than in the older group indicate an age-
dependent difference in the weight of genetic effects, at least for early-onset AMI among Kore-
ans. This suggests that adjusting its effect weight depending on age can improve the contribu-
tion of the PRS to the conventional model, and thus, as one becomes older, early-assessement
of PRSs for AMI can be combined with periodically measured conventional risk factors to
stratify individuals who have different trajectories of AMI risk and predict the early events
associated with AMI. Hence, the prediction of the risk trajectory with the age-adjusted PRS
weighing model can be beneficial, especially in young individuals, because the geneticrisk
could be attenuated by adhering to a healthy lifestyle as early as possible [20,21].
For example, it has been reported that significant coronary atherosclerosis already exists in
young and asymptomatic people [22]. As the number of cardiovascular risk factors increases,
so does the severity of asymptomatic coronary atherosclerosis in young people [23]. If the risk
of CAD in a younger person can be determined before noticing any cardiovascular risk factors,
early risk modification and prevention of asymptomatic coronary atherosclerosis can be
achieved. By doing so, it would be possible to reduce the prevalence of CAD and achieve pri-
mary prevention. Thus, the PRS can serve as a guide to achieving primary prevention.
We found that the association of the PRS with repeat revascularization events after PCI was
significant, but the association with repeat revascularization was insignificant for conventional
risk factors. This may suggest that the PRS can better explain the possibility of repeat revascu-
larization and be a practical measure for guiding secondary prevention strategies. For example,
after PCI, a clinician may recommend patients with a high PRS to visit a hospital more fre-
quently than those with a low PRS. Therefore, closer follow-ups with optimal medical treat-
ments in high PRS groups would be recommended. And such a PRS application for the
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follow-up and treatment will possibly become more effective and precise if the confounding
effect of clinical factors such as detailed information of diseases, subgroups of disease, drugs
taking, method of treatment, kind of outcomes, durations through onset, treatment, discharge,
and follow-up are considered together.
The classification accuracy of the PRS alone and the additive contribution of the PRS to the
six conventional risk factors were modest; this was investigated on a previous PRS study [2].
The performance of the PRS could be affected by various factors such as the population ethnic-
ities, disease types, and biological pathways for the construction and application of the PRS
[24–28]. This indicates that improved applicability may be expected if the PRS is fine-tuned to
such factors.
In conclusion, we found that the Caucasian population-based PRS is applicable to Korean
patients with early-onset AMI. The PRS improved the classification accuracy of the conven-
tianl factors for early-onset AMI with a statistical significance, although the amount of
improvement was modest. The PRS was a independent factor to predict future repeat revascu-
larization events after PCI.
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